Peptidylarginine deiminases (PADs) catalyse a post-translational modification of proteins through the conversion of arginine residues into citrullines. The existence of four isoforms of PAD (types I, II, III and IV) encoded by four different genes, which are distinct in their substrate specificities and tissue-specific expression, was reported in rodents. In the present study, starting from epidermis polyadenylated RNA, we cloned by reverse transcriptase-PCR a full-length cDNA encoding human PAD type I. The cDNA was 2711bp in length and encoded a 663-amino-acid sequence. The predicted protein shares 75% identity with the rat PAD type I sequence, but displays only 50—57% identity with the three other known human isoforms. We have described the organization of the human PAD type I gene on chromosome 1p36. A recombinant PAD type I was produced in Escherichia coli and shown to be enzymically active. Human PAD type I mRNAs were detected by reverse transcriptase-PCR not only in the epidermis, but also in various organs, including prostate, testis, placenta, spleen and thymus. In human epidermis extracts analysed by Western blotting, PAD type I was detected as a 70kDa polypeptide, in agreement with its predicted molecular mass. As shown by immunohistochemistry, the enzyme was expressed in all the living layers of human epidermis, with the labelling being increased in the granular layer. This is the first description of the human PAD type I gene and the first demonstration of its expression in epidermis.
Skip Nav Destination
Article navigation
February 2003
- PDF Icon PDF LinkFront Matter
Research Article|
February 15 2003
cDNA cloning, gene organization and expression analysis of human peptidylarginine deiminase type I
Marina GUERRIN;
Marina GUERRIN
1
∗Department of Epidermal Differentiation and Rheumatoid Autoimmunity, Toulouse-Purpan Pathophysiology Center, INSERM U563 - P. Sabatier University (IFR30, INSERM-CNRS-P. Sabatier Université-Centre Hospitalier Universitaire), 37 allées J. Guesde, 31073 Toulouse, France,
Search for other works by this author on:
Akihito ISHIGAMI;
Akihito ISHIGAMI
1
†Department of Bioactivity Regulation, Tokyo Metropolitan Institute of Gerontology, 35-2 Sakae-cho, 173-0015 Itabashi-ku, Tokyo, Japan
2To whom correspondence should be addressed (e-mail msimon@cict.fr).
Search for other works by this author on:
Marie-Claire MÉCHIN;
Marie-Claire MÉCHIN
∗Department of Epidermal Differentiation and Rheumatoid Autoimmunity, Toulouse-Purpan Pathophysiology Center, INSERM U563 - P. Sabatier University (IFR30, INSERM-CNRS-P. Sabatier Université-Centre Hospitalier Universitaire), 37 allées J. Guesde, 31073 Toulouse, France,
Search for other works by this author on:
Rachida NACHAT;
Rachida NACHAT
∗Department of Epidermal Differentiation and Rheumatoid Autoimmunity, Toulouse-Purpan Pathophysiology Center, INSERM U563 - P. Sabatier University (IFR30, INSERM-CNRS-P. Sabatier Université-Centre Hospitalier Universitaire), 37 allées J. Guesde, 31073 Toulouse, France,
Search for other works by this author on:
Séverine VALMARY;
Séverine VALMARY
∗Department of Epidermal Differentiation and Rheumatoid Autoimmunity, Toulouse-Purpan Pathophysiology Center, INSERM U563 - P. Sabatier University (IFR30, INSERM-CNRS-P. Sabatier Université-Centre Hospitalier Universitaire), 37 allées J. Guesde, 31073 Toulouse, France,
Search for other works by this author on:
Mireille SEBBAG;
Mireille SEBBAG
∗Department of Epidermal Differentiation and Rheumatoid Autoimmunity, Toulouse-Purpan Pathophysiology Center, INSERM U563 - P. Sabatier University (IFR30, INSERM-CNRS-P. Sabatier Université-Centre Hospitalier Universitaire), 37 allées J. Guesde, 31073 Toulouse, France,
Search for other works by this author on:
Michel SIMON;
Michel SIMON
2
∗Department of Epidermal Differentiation and Rheumatoid Autoimmunity, Toulouse-Purpan Pathophysiology Center, INSERM U563 - P. Sabatier University (IFR30, INSERM-CNRS-P. Sabatier Université-Centre Hospitalier Universitaire), 37 allées J. Guesde, 31073 Toulouse, France,
2To whom correspondence should be addressed (e-mail msimon@cict.fr).
Search for other works by this author on:
Tatsuo SENSHU;
Tatsuo SENSHU
3
†Department of Bioactivity Regulation, Tokyo Metropolitan Institute of Gerontology, 35-2 Sakae-cho, 173-0015 Itabashi-ku, Tokyo, Japan
Search for other works by this author on:
Guy SERRE
Guy SERRE
∗Department of Epidermal Differentiation and Rheumatoid Autoimmunity, Toulouse-Purpan Pathophysiology Center, INSERM U563 - P. Sabatier University (IFR30, INSERM-CNRS-P. Sabatier Université-Centre Hospitalier Universitaire), 37 allées J. Guesde, 31073 Toulouse, France,
Search for other works by this author on:
Biochem J (2003) 370 (1): 167–174.
Article history
Received:
June 05 2002
Revision Received:
October 18 2002
Accepted:
November 05 2002
Accepted Manuscript online:
November 05 2002
Citation
Marina GUERRIN, Akihito ISHIGAMI, Marie-Claire MÉCHIN, Rachida NACHAT, Séverine VALMARY, Mireille SEBBAG, Michel SIMON, Tatsuo SENSHU, Guy SERRE; cDNA cloning, gene organization and expression analysis of human peptidylarginine deiminase type I. Biochem J 15 February 2003; 370 (1): 167–174. doi: https://doi.org/10.1042/bj20020870
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.